- Home
- STHO vs VIGL Comparison
STHO vs VIGL Comparison
Compare STHO & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- VIGL
- Stock Information
- Founded
- STHO N/A
- VIGL 2020
- Country
- STHO United States
- VIGL United States
- Employees
- STHO N/A
- VIGL N/A
- Industry
- STHO Real Estate
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- VIGL Health Care
- Exchange
- STHO Nasdaq
- VIGL Nasdaq
- Market Cap
- STHO 153.3M
- VIGL 141.5M
- IPO Year
- STHO N/A
- VIGL 2022
- Fundamental
- Price
- STHO $11.21
- VIGL $3.00
- Analyst Decision
- STHO
- VIGL Buy
- Analyst Count
- STHO 0
- VIGL 5
- Target Price
- STHO N/A
- VIGL $16.80
- AVG Volume (30 Days)
- STHO 37.1K
- VIGL 51.3K
- Earning Date
- STHO 11-05-2024
- VIGL 11-07-2024
- Dividend Yield
- STHO N/A
- VIGL N/A
- EPS Growth
- STHO N/A
- VIGL N/A
- EPS
- STHO 6.15
- VIGL N/A
- Revenue
- STHO $117,752,000.00
- VIGL N/A
- Revenue This Year
- STHO N/A
- VIGL N/A
- Revenue Next Year
- STHO N/A
- VIGL N/A
- P/E Ratio
- STHO $1.82
- VIGL N/A
- Revenue Growth
- STHO 13.35
- VIGL N/A
- 52 Week Low
- STHO $11.02
- VIGL $2.47
- 52 Week High
- STHO $15.31
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- STHO 26.82
- VIGL 32.87
- Support Level
- STHO $11.02
- VIGL $2.89
- Resistance Level
- STHO $12.44
- VIGL $3.26
- Average True Range (ATR)
- STHO 0.37
- VIGL 0.22
- MACD
- STHO -0.07
- VIGL -0.08
- Stochastic Oscillator
- STHO 12.84
- VIGL 9.40
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.